This HTML5 document contains 133 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n11	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
n12	http://dx.doi.org/10.1161/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q38384300

rdf:type

wikibase:Item

schema:description

artículu científicu espublizáu en 2016 articolo scientifico artikel ilmiah article científic 2016年の論文 ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ mokslinis straipsnis επιστημονικό άρθρο bilimsel makale vitskapeleg artikkel სამეცნიერო სტატია 2016年论文 научна статия artigo científico (publicado na 2016) מאמר מדעי vedecký článok 2016年論文 2016年论文 artikulong pang-agham wissenschaftlicher Artikel مقالة علمية мақолаи илмӣ videnskabelig artikel (udgivet 2016) 2016年论文 scientific article vetenskaplig artikel บทความทางวิทยาศาสตร์ 2016年論文 научни чланак naučni članak scientific article tieteellinen artikkeli bài báo khoa học 2016년 논문 2016年论文 2016 nî lūn-bûn articol științific scienca artikolo vědecký článek 2016年論文 artykuł naukowy գիտական հոդված teaduslik artikkel artikull shkencor artículo científico publicado en 2016 artigo científico (publicado na 2016) мақолаи илмӣ article scientifique (publié 2016) 2016年论文 مقالهٔ علمی 2016年論文 научная статья سائنسی مضمون tudományos cikk artigo científico article scientific vitenskapelig artikkel наукова стаття, опублікована в листопаді 2016 scientific article 2016年论文 wetenschappelijk artikel 2016年論文 научни чланак

p:P577

wds:Q38384300-52C0A822-CB0F-45BD-8164-B4AB06C6DD5A

wdt:P577

2016-11-14T00:00:00Z

p:P407

wds:Q38384300-25B26A9B-8715-48A5-9F2F-F5975E07B08E

wdt:P407

wd:Q1860

p:P2093

wds:Q38384300-57DCF6BB-B354-468A-A501-364BF0BDD2B4 wds:Q38384300-5498A3AA-F947-4604-8B62-435863E7C50D wds:Q38384300-498183F3-24BF-4B20-ACEE-E34FC6E15437 wds:Q38384300-2AAFE96B-446E-477A-9712-A904901FB563 wds:Q38384300-4050E46E-5BCF-401A-9456-546E6178FE5B wds:Q38384300-21E54FF0-7DF6-4E5F-9382-4334756DCD6D wds:Q38384300-0CC2A53B-2FA6-4BB1-A8F9-7282A5626356 wds:Q38384300-0DDB7591-A9F0-48D3-A4F0-3C7EB617B451 wds:Q38384300-08C1B838-54FC-4193-8E76-858227A95536 wds:Q38384300-D027CF46-00AB-4EB5-81C0-F335BB14F070 wds:Q38384300-DB375790-F547-47E3-854D-7E5DB0E8C2CF wds:Q38384300-BE9948F8-F4A6-41E6-A99F-4E2CBF542BF2 wds:Q38384300-AC39C778-D5DE-4533-9B50-CABD5EF1EEF2 wds:Q38384300-6E4BE920-A924-472E-8CC2-85ADBD945C8F

wdt:P2093

Olga Bandman Samuel Z Goldhaber C Michael Gibson Russel Hull Douglas Arbetter Gerald Chi Yazan Daaboul Purva Jain APEX Investigators Serge Korjian Alexander T Cohen Rim Halaby Adrian F Hernandez Alex Gold

rdfs:label

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

skos:prefLabel

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

schema:name

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

p:P50

wds:Q38384300-8DE524E5-A0C9-48F1-BA80-3DD0C14EA2C2 wds:Q38384300-B5E5972D-C474-4572-B090-23386D8E6E79

wdt:P50

wd:Q77735352 wd:Q62914910

p:P1476

wds:Q38384300-60D60B21-8D67-41C0-868E-D17D6721D524

wdt:P1476

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

p:P304

wds:Q38384300-E7C13469-F6F5-4DEA-8D0E-68F42DCCA048

wdt:P304

648-655

p:P31

wds:Q38384300-9AC99814-FE08-4657-BDF8-15529C6A6796

wdt:P31

wd:Q13442814

p:P921

wds:Q38384300-4C6388AE-C74B-4D3F-8965-5C0D4A0BC73F wds:Q38384300-933A276B-189D-4382-BEE3-F19A52984B33 wds:Q38384300-F9AC2153-BDAF-4833-84FB-8F184CFDA20C

wdt:P921

wd:Q9397786 wd:Q4898219 wd:Q3140971

p:P698

wds:Q38384300-853CF7E4-1FA7-410E-BC68-A6AA43D21FCE

wdtn:P698

n11:27881569

wdt:P698

27881569

p:P1433

wds:Q38384300-B30CCBB2-0353-4A7F-B58C-11DD8F8FD872

wdt:P1433

wd:Q578091

p:P433

wds:Q38384300-AA89CE31-5C8B-4FB2-BF3F-324717CBFCF1

p:P478

wds:Q38384300-86969D05-118A-4D6A-A20F-17258F68A5D2

wdt:P433

7

wdt:P478

135

p:P356

wds:Q38384300-BD9BB9F1-6B4D-426F-B07D-10FA17351879

wdtn:P356

n12:CIRCULATIONAHA.116.025427

wdt:P356

10.1161/CIRCULATIONAHA.116.025427